BLSH three-lens brief
Evidence-based stock research on BLSH. Three independent lenses — Foundation, Expansion, Climate — examine live data from SEC filings, the Federal Reserve, and market feeds. Every claim traces to its primary source.
Performance
Outperforming SPY by 51.2pp over 30 days. · Currently unprofitable on a trailing basis — no P/E multiple available.
- Outperforming SPY by 51.2pp over 30 days.
- Currently unprofitable on a trailing basis — no P/E multiple available.
- Negative free cash flow last quarterly (-$408.92M).
BLSH closed at $33.88 (-1.34%) as of 2026-09-11. Market cap: $5.14B. Price is above the 50-day MA and below the 200-day MA. Positives: outperforming SPY by 51.2pp over 30 days.. Concerns: currently unprofitable on a trailing basis — no P/E multiple available.; negative free cash flow last quarterly (-$408.92M).. Last quarter: Revenue $92.60M, net income -$270.19M, free cash flow -$408.92M.
Why three lenses on BLSH, not one.
A single reasoning model has blind spots it doesn’t know about. We examine BLSHacross Foundation (fundamentals), Expansion (growth runway and market expansion), and Climate (macro/sector). Disagreement between lenses is surfaced, not hidden — it’s how you know when HOLD is the honest call.
Read the full methodologyDrop it in your newsletter or blog.
Free to embed. Updates every 6 hours. Links back to the full brief.
<iframe src="https://clearpathinvest.app/embed/BLSH" width="100%" height="420" frameborder="0" loading="lazy" title="ClearPath BLSH brief"></iframe>